StockData
Interpace Biosciences, Inc. logo

Interpace Biosciences, Inc. (IDXG) stock

IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/30
$5.00−0.15 (-2.91%)

Close on Oct 19, 2026Market cap $138.57MP/E 5.6Yield –

Interpace Biosciences r&d expenses

Research and development expenses are spending on new products and technology.

Interpace Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $594.00K, down 19.9% year over year. For fiscal 2025 it was $642.00K, down 5.0% from the year before. Over ten years it grew -11.9% a year on average. The highest annual figure on record is $2.81M in fiscal 2019.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$642.00K-5.0%
FY2024Dec 31, 2024$676.00K+6.3%
FY2023Dec 31, 2023$636.00K-9.5%
FY2022Dec 31, 2022$703.00K-52.9%
FY2021Dec 31, 2021$1.49M-46.6%
FY2020Dec 31, 2020$2.80M-0.5%
FY2019Dec 31, 2019$2.81M+32.3%
FY2018Dec 31, 2018$2.12M+45.4%
FY2017Dec 31, 2017$1.46M-11.3%
FY2016Dec 31, 2016$1.65M-28.1%
FY2015Dec 31, 2015$2.29M+798.8%
FY2014Dec 31, 2014$255.00K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$149.00K-13.9%
Q1 FY2026Mar 31, 2026$153.00K-13.6%
Q4 FY2025Dec 31, 2025$142.00K-26.4%
Q3 FY2025Sep 30, 2025$150.00K-24.6%
Q2 FY2025Jun 30, 2025$173.00K+18.5%
Q1 FY2025Mar 31, 2025$177.00K+29.2%
Q4 FY2024Dec 31, 2024$193.00K+27.0%
Q3 FY2024Sep 30, 2024$199.00K+33.6%
Q2 FY2024Jun 30, 2024$146.00K-21.5%
Q1 FY2024Mar 31, 2024$137.00K-8.1%
Q4 FY2023Dec 31, 2023$152.00K+97.4%
Q3 FY2023Sep 30, 2023$149.00K-22.0%
Q2 FY2023Jun 30, 2023$186.00K-8.8%
Q1 FY2023Mar 31, 2023$149.00K-35.5%
Q4 FY2022Dec 31, 2022$77.00K-75.6%
Q3 FY2022Sep 30, 2022$191.00K-40.7%
Q2 FY2022Jun 30, 2022$204.00K-51.9%
Q1 FY2022Mar 31, 2022$231.00K-63.7%
Q4 FY2021Dec 31, 2021$315.00K-53.1%
Q3 FY2021Sep 30, 2021$322.00K-57.8%
Q2 FY2021Jun 30, 2021$424.00K-22.9%
Q1 FY2021Mar 31, 2021$637.00K-21.3%
Q4 FY2020Dec 31, 2020$672.00K-13.6%
Q3 FY2020Sep 30, 2020$763.00K-11.0%
Q2 FY2020Jun 30, 2020$550.00K-15.0%
Q1 FY2020Mar 31, 2020$809.00K+53.2%
Q4 FY2019Dec 31, 2019$778.00K+30.5%
Q3 FY2019Sep 30, 2019$857.00K+68.0%
Q2 FY2019Jun 30, 2019$647.00K+24.9%
Q1 FY2019Mar 31, 2019$528.00K+5.4%
Q4 FY2018Dec 31, 2018$596.00K+130.1%
Q3 FY2018Sep 30, 2018$510.00K+5.6%
Q2 FY2018Jun 30, 2018$518.00K+25.4%
Q1 FY2018Mar 31, 2018$501.00K+63.7%
Q4 FY2017Dec 31, 2017$259.00K-15.9%
Q3 FY2017Sep 30, 2017$483.00K-26.7%
Q2 FY2017Jun 30, 2017$413.00K–
Q1 FY2017Mar 31, 2017$306.00K–
Q4 FY2016Dec 31, 2016$308.00K–
Q3 FY2016Sep 30, 2016$659.00K–

More Interpace Biosciences figures

See a number that looks wrong?